The leukemia treatment landscape is evolving nearly in real timefrom the emergence of chemotherapy-free combination regimens for chronic lymphocytic leukemia (CLL) to the rise of CAR (chimeric antigen receptor) T-cell immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Even in acute myeloid leukemia (AML)a longtime challenge in the hematological malignancieswe are finally seeing the treatment armamentarium expand.
For the patients we serve at The Leukemia & Lymphoma Society (LLS), this evolution cant come soon enough. For 4 decades, a drought in therapeutic advances for AML meant patients were treated with a one-size-fits-all-approach, centered on traditional cytotoxic chemotherapy and/or a stem cell transplant. But this approach fails too many patients. Long-term survival for older patients, who may not be able to tolerate aggressive therapy, remains dismal. Its estimated that only 10% of older patients will survive 5 years after diagnosis.1
At the other end of the spectrum, while the standard of care is curative for many children with AML, those who do survive experience long-term complications, such as cardiotoxicity, neurocognitive impairment, and endocrine disorders. New treatments are urgently needed for children who relapse or do not respond to chemotherapy.
Precision Medicine and FLT3 Inhibitors
Thankfully, state-of-the-art genomic technologies are improving our understanding of the genetic and molecular underpinnings of AMLa complex constellation of diseasesand driving more precision medicine. Recognizing the pressing need for novel therapeutics, LLS invests approximately a quarter of our research dollars annually in AML. This work is complemented by our Beat AML Master Clinical Trialthe first collaborative precision medicine clinical trial in a blood cancer, which has been in progress since November 2016.
Our long-term investment in research is paying off in the impact for patients. Since 2017, there has been a proliferation of newly approved treatments for AML. The first of these therapies, midostaurin (Rydapt, Tauritmo), was approved for adults with newly diagnosed AML who are FLT3 mutation-positive, in combination with chemotherapy.
Approximately 30% of AML patients have a mutation in the FLT3 gene, which is associated with a particularly poor prognosis.2 As the first FLT3 inhibitor approved by the FDA, midostaurin marked a new wave of treatments targeting specific cytogenetic and molecular abnormalities. Since then, a second FLT3 inhibitor called gilteritinib (Xospata) was approved for adults with relapsed or refractory AML. Today, our Beat AML trial is testing gilteritinib in the frontline setting among newly diagnosed patients with FLT3-mutated AML, as a monotherapy and in combination with other drugs, showing encouraging results.
IDH and BCL-2 Inhibitors
Whats more, IDH inhibitors are improving outcomes for patients with AML. IDH1 and IDH2 mutations occur in about 20% of AML cases.3 Ivosidenib (Tibsovo) is approved for adults with IDH1-mutated relapsed or refractory AML as well as newly diagnosed patients with IDH1 mutation who are at least 75 years old or are ineligible for intensive induction chemotherapy. Most recently, the combination of ivosidenib and azacitidine (Vidaza) has shown impressive improvements in event-free survival and overall survival over azacitidine alone among adults with previously untreated IDH1-mutated AML, based on topline data from the global, phase 3 AGILE trial (NCT03173248).4
Meanwhile, enasidenib (Idhifa)approved for adults with relapsed or refractory AML with an IDH2 mutationis showing promise as an effective first-line treatment for older patients who are newly diagnosed. During the 62nd American Society of Hematology Annual Meeting, Eytan Stein, MD, from Memorial Sloan Kettering Cancer Center, presented data from a Beat AML sub-study, which found that 47% of patients had a complete response to enasidenib.5 Patients who did not respond to enasidenib alone were given the drug in combination with azacitidine, and 41% of these patients achieved a complete response. Beat AML continues to test enasidenib with other novel agents in patients who are resistant to the drug on its own.
Another FDA-approved game-changer for both CLL and AML is the BCL-2 inhibitor venetoclax (Venclexta), targeting the apoptotic pathway and metabolic function of leukemic cells. LLS has funded research into the development of venetoclax for over 20 years and continues to advance projects focused on overcoming treatment resistance and optimizing combinations.
For example, LLS-funded researcher Daniel Pollyea, MD, MS, from the University of Colorado, recently showed that venetoclax combined with azacitidine was far more effective than azacitidine alone for previously untreated patients with AML who have IDH1 and IDH2 mutations and cannot withstand intensive treatment due to age or comorbidities. Between 72% to 78% of patients treated with the combination responded, compared with 7% to 10% who received azacitidine with a placebo.6 Further, median overall survival was 24.5 months for the combination vs 6.2 months for the azacitidine and placebo.
Among the other recently approved therapies for AML is the anti-CD33 monoclonal antibody gemtuzumab ozogamicin (Mylotarg); the Hedgehog signaling pathway inhibitor glasdegib (Daurismo), CC-486 (Onureg), the first maintenance treatment for AML; and liposomal daunorubicin and cytarabine (Vyxeos), an innovative reformulation of 2 chemotherapies for certain types of newly diagnosed secondary AML. Notably, both liposomal daunorubicin and cytarabine and gemtuzumab ozogamicin are approved for adult and pediatric secondary or therapy-related AML.
LLS recognized the potential of this fixed combination liposomal treatment back in 2009 when we supported it through our Therapy Acceleration Program (LLS TAP), our strategic venture philanthropy funding initiative. LLS partnered with Celator Pharmaceuticals, which Jazz Pharmaceuticals later acquired, to fast-track development of this therapy for adults with AML.
Through LLS TAP, were also advancing next-generation immunotherapies for AML, including a first-in-class antibody targeting myeloid checkpoint LILRB4 from Immune-Onc Therapeutics and an adoptive cellular therapy from NexImmune that leverages nanoparticle-trained CD8-positive T cells.
With AML research flourishing, we can expect to see the rising tide of novel approaches continue. Among the most promising areas are harnessing immunotherapy, identifying pre-leukemia conditions, exploiting metabolic vulnerabilities, and developing epigenetic therapies. For example, with LLS support, Jolanta Grembecka, PhD, from the University of Michigan, is developing first-in-class small molecule inhibitors of the ASH1L SET domain.
The Future of Clinical Trials
While were seeing progress in AML, there is still much more work to be done. Clinical research in the era of precision medicine is homing in on ever smaller groups of patients with specific disease subtypes or characteristics. Too many trials fail to meet their goals because there are simply not enough patients enrolled. To address this challenge, we need to reimagine how clinical trials are conducted.
At LLS, our vision is for our Beat AML Master Clinical Trial to not only bring new therapies to patients with AML faster, but also serve as a model for future clinical trials. With its flexible, collaborative structure, the trial is testing multiple targeted therapies among newly diagnosed patients with AML aged 60 or older in multiple study arms simultaneously.
Already, the trial has achieved its primary end point by showing that genomic analysis to identify AML subtypes can be completed within an unprecedented 7 daysgiving patients and their providers ample time to make more personalized treatment decisions.7 Further, weve demonstrated that using genetic information to match patients to targeted therapies leads to better survival rates. The median overall survival for patients in Beat AML was 12.8 months vs 3.9 months for patients on the standard of care.
Recently, LLS published a paper in Therapeutic Innovation & Regulatory Science that outlines the Beat AML blueprint, including how to integrate operational strategies with new electronic technologies. Our hope is that the scientific and medical communities leverage these learnings to help even more patients with cancer.
At the same time, with the COVID-19 pandemic exacerbating existing health inequities, its essential that we ensure equitable access to clinical trials. Racial and ethnic minorities, rural residents, and individuals with low incomes are overwhelmingly underrepresented in clinical research. LLS is setting out to change this through our LLS IMPACT (Influential Medicine Providing Access to Clinical Trials) Research Grants.
By creating a hub-and-spoke infrastructure between clinical trial leaders at major cancer centers and community-based oncologists, this program will help bring more trials to patients at the community setting. We awarded the first round of funding to 3 major cancer centers that reach underserved patient populations in different parts of the country: Mayo Clinic Cancer Center, Vanderbilt University Medical Center, and Weill Cornell Medicine. Partnering with community-based oncologists across the clinical trial ecosystem is key to increasing and diversifying enrollment.
Finally, its vitally important that our youngest, most vulnerable patients benefit from precision medicine. Childhood AML is distinct from adult AMLdriven by different mechanisms and with different mutationsyet there is a critical gap in therapies designed just for children. At LLS, our goal is no less than a wholesale shift in the standard of care, moving toward safer, more effective treatments that precisely target cancer without harming the rest of the body.
Achieving this goal requires disrupting the 1-agent-at-a-time model in pediatric oncology drug development. LLS is driving an unprecedented collaboration to launch the first global precision medicine clinical trial for pediatric acute leukemia, called LLS PedAL. LLS PedAL will test multiple novel therapies simultaneously among children with relapsed acute leukemia at more than 200 clinical sites worldwide. Through LLS PedAL, we will identify and validate underlying molecular drivers of disease and match patients with the most promising treatments based on their unique tumor biology. Ultimately, every child who enters the trial will receive screening to determine their specific biological markers. LLS will be submitting the Investigational New Drug Application to the FDA this fall, with the goal of beginning LLS PedAL by the end of the year.
Critical to LLS PedAL is equipping researchers and clinicians with a wealth of clinical and genomic information. A team at the University of Chicago Pediatric Cancer Data Commons (PCDC), led by Samuel L. Volchenboum, MD, PhD, MS, is spearheading a project to gather pediatric acute leukemia data from multiple institutions, establish a common language to analyze the data, and make those data available to researchers worldwide. Clinicians will then be able to assess patterns and identify new areas of exploration much more nimbly.
By breaking down traditional clinical and data silos, embracing new clinical trial models that put patients at the center of their care, and improving access to these trials, we can bring precision medicine to more patients and change the future of AML treatment.
1. Lai C, Doucette K, Norsworthy K. Recent drug approvals for acute myeloid leukemia. J Hematol Oncol. 2019;12(100). https://doi.org/10.1186/s13045-019-0774-x
2. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299312. https://doi.org/10.1038/s41375-018-0357-9
3. Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J. 2021;11(107). https://doi.org/10.1038/s41408-021-00497-1
4. Servier. Servier announces positive topline data from the global phase 3 study of TIBSOVO (ivosidenib tablets) in combination with azacitidine in patients with previously untreated IDH1-mutated acute myeloid leukemia. PR Newswire. Published August 2, 2021. https://www.prnewswire.com/news-releases/servier-announces-positive-topline-data-from-the-global-phase-3-study-of-tibsovo-ivosidenib-tablets-in-combination-with-azacitidine-in-patients-with-previously-untreated-idh1-mutated-acute-myeloid-leukemia-301345783.html
5. Stein EM, Huang Y, Borate U, et al. Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial. Blood. 2020;136 (Supplement 1):27-30. https://doi.org/10.1182/blood-2020-143265
6. Pollyea DA, DiNardo CD, Arellano ML, et all. Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations. Blood. 2020;136 (Supplement 1):5-7. https://doi.org/10.1182/blood-2020-134736
7. Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat. Med. 2020;26:18521858. https://doi.org/10.1038/s41591-020-1089-8
- COVID-19: Researchers warn against overhyping early-stage therapies - Medical News Today - October 26th, 2021
- OpRegen Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D. - Yahoo Finance - October 26th, 2021
- Insights & Outcomes: Place cells, planarians, and 'prewet' proteins - Yale News - October 26th, 2021
- IMAC Holdings The Back Space Announces the Completion of Two Additional Retail Spinal Care Locations - Yahoo Finance - October 26th, 2021
- JEFFERSON PARISH PARTNERS WITH LOUISIANA DEPARTMENT OF HEALTH TO ADMINISTER FREE FLU SHOTS AND COVID-19 VACCINES ON NOVEMBER 6, 2021 - 10-25-YYYY -... - October 26th, 2021
- Male Infertility Could Be Treated With Monkey Cells; New Study Shows How These Animals Could Help Address the Condition - Science Times - October 26th, 2021
- Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients - Yahoo... - October 26th, 2021
- New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia - News-Medical.Net - October 25th, 2021
- Getting to Know Kate Roth at Beacon Integrative Medical Center in Rexburg - East Idaho News - October 25th, 2021
- Global Cell Therapy Market Report 2021-2028 - Growing Adoption of Regenerative Medicine & Introduction of Novel Platforms and Technologies -... - October 25th, 2021
- Vertex reports positive results for first patient in Type 1 diabetes trial - BetaBoston - October 23rd, 2021
- Morris receives grant for stem cell research - The Source - Washington University Record - October 23rd, 2021
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes - PMLiVE - October 23rd, 2021
- McLaughlin Research Institute receives $5 million gift to support neurology studies - Great Falls Tribune - October 23rd, 2021
- AML medication and treatment: What to know - Medical News Today - October 23rd, 2021
- U S Stem Cell : USRM to Focus on Animal Health and Lead Pet-Care Innovation - Marketscreener.com - October 19th, 2021
- Opinion: Why Colin Powell's death should not be framed as the death of a vaccinated person - Poynter - October 19th, 2021
- Quris combines AI with patient on a chip to speed drug development and reduce animal testing - TechCrunch - October 19th, 2021
- Dr. Helen Heslop elected to the National Academy of Medicine - Baylor College of Medicine News - October 19th, 2021
- Researchers report long-lasting effects of gene therapy in children with deadly immune disorder - News-Medical.Net - October 19th, 2021
- Coronavirus: How does misinformation spread, and how can we stop it? - The Jerusalem Post - October 17th, 2021
- Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL - OncLive - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - Business Wire - October 17th, 2021
- Global Stem Cell and Primary Cell Culture Medium Market 2021 Trends and Leading Players Analysis 2027 Merck, STEMCELL Technologies, Irvinesci, Cell... - October 15th, 2021
- Dr. Erba on the Evolution of Treatment in MCL - OncLive - October 15th, 2021
- After no stem cell donors stepped up to saved her son, mom continues to help others facing the same challenge - Chicago Tribune - October 15th, 2021
- International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire - October 15th, 2021
- Are 'robot massages' the future of muscle repair? - Medical News Today - October 15th, 2021
- What the FDA Panel's Moderna Booster Shot Vote Means and What's Next - NBC Chicago - October 15th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 15th, 2021
- R3 Stem Cell & Exosome Therapy: Joint & Back Pain, Avoid ... - October 13th, 2021
- Stem Cell PhD Program | Institute for Stem Cell Biology ... - October 13th, 2021
- New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease - Newswise - October 13th, 2021
- Repurposed Drug Reverses Signs of Alzheimers in Mice, Human Cells - The Scientist - October 13th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - StreetInsider.com - October 13th, 2021
- What the latest COVID research says about breakthrough cases and transmission : Shots - Health News - NPR - October 13th, 2021
- HNF collaborates with Rarebase on a Drug Discovery Platform to develop treatments for Charcot-Marie-Tooth (CMT) - PRNewswire - October 13th, 2021
- Autologous HSCT Continues to Show Sustained Benefit in MCL, But Targeted Therapies May Challenge its Role as Standard Frontline Treatment -... - October 13th, 2021
- Bartolo Coln, Winner Of The Cy Young, Wins Lawsuit In Case Of Stem Cell Treatment To Which He Was Subjected Before His Return To The Major Leagues. -... - October 11th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Letter. - Yahoo Finance - October 11th, 2021
- Top US Leukemia Experts from Academia, Industry and Public Sector Coming Together at Acute Myeloid Leukemia Conference on October 22 - OncLive - October 11th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 11th, 2021
- Treating Early Relapse in Follicular Lymphoma - Targeted Oncology - October 11th, 2021
- Humans and Chimpanzees Use a Part of Their DNA in Different Ways - Technology Networks - October 11th, 2021
- A stem cell treatment for MS offers some patients hope. But is it hope that will last? - WHYY - October 9th, 2021
- CAR T Offer New Treatment Option for Non-Hodgkin Lymphoma - Targeted Oncology - October 9th, 2021
- FDA Advisory Committee Recommends Maribavir to Treat Cytomegalovirus CMV Infection and Disease - Contagionlive.com - October 9th, 2021
- What surgeons are saying about regenerative medicine in 2021 - Becker's Orthopedic & Spine - October 9th, 2021
- Study illuminates how BRD4 protein directs the spatial organization of DNA within cell nucleus - News-Medical.net - October 9th, 2021
- Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma - OncLive - October 9th, 2021
- Anti-CD47 Therapy and Other New Approaches to the Treatment of Myelodysplastic - Targeted Oncology - October 9th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- Seattle Stem Cell Therapy Clinic - Seattle Sports Medicine ... - October 7th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- New Stem Cell Approach Through Using Wavelength Laser Might have Discovered Why Humans Lose Hair - Tech Times - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - WMTV - NBC15 - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Northwesterns SPORE has made advances in understanding the genetic basis of glioblastoma - News-Medical.Net - October 5th, 2021
- NextCure Announces New Appointments to its Board of Directors - GlobeNewswire - October 5th, 2021
- Therapy and Prevention Strategies for Myocardial Infarction | IJN - Dove Medical Press - October 3rd, 2021
- Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com - October 3rd, 2021
- Advanced technique offers new insights about the dynamics of gliomas - News-Medical.net - October 3rd, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 2nd, 2021
- The stem cell revolution isnt what you think it is - New Scientist News - October 2nd, 2021
- Stem cell agency gives out $2 million a minute - Capitol Weekly - October 2nd, 2021
- Researching the Safety and Effectiveness of Stem Cells to Treat 'Long Covid' - Entrepreneur - October 2nd, 2021
- United States Regenerative Medicine Markets to 2026: Focus on Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies, Tissue Engineered... - October 2nd, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 2nd, 2021
- Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA - Business Wire - October 2nd, 2021
- Stem Cell Umbilical Cord Blood Market in North America 2021 Sees Growth Due to Rising Spending Capacity and Suitable Payment Plans - PRNewswire - October 2nd, 2021
- BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS - BioSpace - October 2nd, 2021
- Macomics Announces New Hires that Expands its Macrophage-based Drug Discovery R&D Team - BioSpace - October 2nd, 2021
- Stanford neuroscientist's 'assembloids' pave the way for innovative brain research - Scope - October 2nd, 2021
- At the crossroads of reproductive and regenerative medicine: new opportunities for preserving and restoring fertility - ESHRE - September 25th, 2021
- Doctors Debate: Do CAR T Cells and Transplantation Both Have a Place in Aggressive B-Cell Lymphoma Treatment? - Targeted Oncology - September 25th, 2021
- Global Stem Cell Alopecia Treatment Market 2021 Development Status,Industry Insights and Forecast Research Report 2027 Stillwater Current -... - September 25th, 2021
- AML vs. ALL: Differences in symptoms, diagnosis, and survival - Medical News Today - September 25th, 2021
- New gene therapies may soon treat dozens of rare diseases - American Society for Biochemistry and Molecular Biology - September 25th, 2021
- BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program - GlobeNewswire - September 25th, 2021